NCT06233903 2025-01-21
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2 Withdrawn
Clinical Trials
16 trialsNCT04739566 2024-03-25
ANAPLAST-NEO
Saint Petersburg State University, Russia
Phase 2 Withdrawn
NCT04276597 2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Withdrawn
NCT04915144 2023-02-21
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT04713202 2023-02-10
NET-PACS
Big Ten Cancer Research Consortium
Phase 2 Withdrawn
NCT04831567 2022-05-19
MIBNET
AC Camargo Cancer Center
Phase 2 Withdrawn
NCT04672876 2021-12-17
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
University of Chicago
Phase 2 Withdrawn
NCT03901378 2021-01-25
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
Ochsner Health System
Phase 2 Withdrawn
NCT04106843 2020-09-07
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00601289 2020-07-31
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02289144 2019-07-30
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT01048086 2016-06-21
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
Phase 2 Withdrawn
NCT00696930 2015-11-26
Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00227773 2015-10-08
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT00469469 2015-04-22
Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
Dartmouth-Hitchcock Medical Center
Phase 2 Withdrawn
NCT01172717 2013-07-26
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Boston Medical Center
Phase 2 Withdrawn